Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer.
Managing AEs with Gemcitabine Intravesical System in NMIBC
Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma
The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.
FDA Approves Gemcitabine Intravesical System in BCG-Unresponsive NMIBC
In patients who refuse or are ineligible for radical cystectomy, the gemcitabine intravesical system may be given after unsuccessful BCG treatment.
NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer
The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.
TAR-200 Appears Highly Efficacious, Safe in BCG-Unresponsive NMIBC
Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.
Enfortumab Vedotin/Pembrolizumab Improves Survival vs Surgery in MIBC
Patients with cisplatin-ineligible bladder cancer who received enfortumab vedotin plus pembrolizumab and surgery had prolonged survival vs those who received surgery alone.